^
Association details:
Biomarker:No biomarker
Cancer:Esophageal Squamous Cell Carcinoma
Drug:Cejemly (sugemalimab) (PD-L1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Title:

CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma

Published date:
12/08/2023
Excerpt:
CStone Pharmaceuticals...announced that the National Medical Products Administration (NMPA) of China has approved the supplemental biologics license application (sBLA) for sugemalimab (Cejemly) in combination with fluorouracil and platinum-based chemotherapy as first-line treatment of unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).
Secondary therapy:
5-fluorouracil + Chemotherapy